For mutations amenable to exon 44 skipping, the FDA designates Duchenne Agent AOC 1044 as a Rare Pediatric Disease.

Published Date: 23 May 2024

In the second part of 2024, Avidity Biosciences plans to release new cohort data from the phase 1/2 EXPLORE44 trial, which evaluated AOC 1044 in Duchenne muscular dystrophy mutations susceptible to exon 44 skipping.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot